GenFleet Therapeutics (Shanghai) Inc
HKEX:2595
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| CN |
|
GenFleet Therapeutics (Shanghai) Inc
HKEX:2595
|
10.5B HKD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
383.2B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
201.5B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
181.6B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
120.9B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.6B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
87.9B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
43.9B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -409 046.1% |
| 30th Percentile | -1.4% |
| Median | 4.2% |
| 70th Percentile | 10.3% |
| Max | 876.4% |
Other Profitability Ratios
GenFleet Therapeutics (Shanghai) Inc
Glance View
Genfleet Therapeutics (Shanghai), Inc. operates as a commercial-stage biopharmaceutical company. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2025-09-19. The firm provides effective new treatment solutions for tumors, autoimmune and inflammatory diseases, covering target discovery, molecular discovery and evaluation, translational science and clinical development, as well as key chemistry manufacturing and controls aspects including formulation research, process development and quality analysis. The firm is mainly engaged in the development of new molecular entities, novel molecular modalities, investigation of molecular process routes and quality standards, and exploration of differentiated clinical development strategies and paths. The firm mainly primarily operates in the domestic and international markets.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for GenFleet Therapeutics (Shanghai) Inc is -285.3%, which is above its 3-year median of -324.3%.
Over the last 1 years, GenFleet Therapeutics (Shanghai) Inc’s Operating Margin has increased from -363.3% to -285.3%. During this period, it reached a low of -363.3% on Dec 1, 2023 and a high of -285.3% on Jan 31, 2025.
